Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)

ClinicalTrials.gov ID: NCT02080195

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02080195. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLE

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main goal of the study is to determine if bone marrow transplant (BMT) from a less specific pool of donors in combination with high dose cyclophosphamide can induce remission of refractory systemic lupus erythematosus.

Study identification

NCT ID: NCT02080195
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Enrollment: 1 participant

Conditions and interventions

Conditions

Interventions

Cyclophosphamide Drug
Fludarabine Drug
Tacrolimus Drug
Mycophenolate Mofetil Drug
Rabbit antithymocyte globulin Drug
Total body irradiation Radiation
Allogeneic bone marrow transplant Biological

Drug · Radiation · Biological

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 13, 2016 (Actual)
Primary completion: Mar 28, 2017 (Actual)
Completion: Mar 29, 2017 (Actual)
Last update posted: Oct 2, 2019

2016 – 2017

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland	21205	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02080195, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 2, 2019 · Synced Nov 12, 2026